Annual Meeting News

TEL AVIV, Israel--(BUSINESS WIRE)--Similarweb (NYSE: SMWB), a leading digital market intelligence company, welcomed Tamar Rapaport-Dagim to its Board of Directors today, following her election with overwhelming support at Similarweb’s annual general meeting of shareholders. Tamar Rapaport-Dagim is Chief Financial Officer and Chief Operating Officer of Amdocs (NASDAQ: DOX). “As a leader at Amdocs, which provides software and services for communications, media, and financial services companies, T...

MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global leader in AI software and robotics for autonomous nutrition systems, held its Annual General Meeting yesterday, August 25, 2025, at its Munich offices and R&D center. A total of 49.61 percent of share capital was represented. Shareholders approved all seven items on the agenda by a large majority, expressing continued confidence in the Executive Board and the Board of Directors. In his speech, CEO and Founder Nikolas Bullwinkel refle...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Spanish Mountain Gold Ltd. (the "Company" or "Spanish Mountain Gold") (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF) is pleased to announce the results from its Annual General Meeting of shareholders (the “AGM”) held on August 21, 2025. All matters of business as outlined in the Company’s management information circular were approved by shareholders. The Board of Directors of the Company consists of Brent Bergeron, Peter Mah, Lembit Janes, Richard Orazietti...

MENLO PARK, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence at scale, announced today that it will present practical approaches for generating high-validity real-world evidence (RWE) at the International Society for Pharmacoepidemiology (ISPE) 41st Annual Meeting in Washington, D.C. CEO Dan Riskin will share approaches to achieve fit-for-use RWD based on real-world learnings from large pharma collaborations and the FDA-sponsored Verantos-led TRUST and V...

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (Nasdaq: SSYS) (“Stratasys” or the “Company”) today announced that it will hold its 2025 Annual General Meeting of Shareholders (the “Meeting”) on Tuesday, September 30, 2025, at 3:00 p.m. Israel time, at Meitar Law Offices, 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. The record date for shareholders entitled to vote at the Meeting is Wednesday, August 20, 2025. The agenda for the Meeting is as follows: Re-elec...

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (OTCQB: QTIH), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, announced today that at the Annual Meeting of Company’s stockholders (the “Annual Meeting”) held on August 19, 2025, the Company’s stockholders voted to approve (i) the election of Daniel Dickson and James Greene as Class I directors to serve until the Company’s 2028 Annu...

NEW YORK--(BUSINESS WIRE)--The Estée Lauder Companies Inc. (NYSE:EL) announced today that Dana Strong, CBE and Annabelle Yu Long have been nominated by its Board of Directors for election as directors at the upcoming annual meeting of stockholders to be held on November 13, 2025. Ms. Strong and Ms. Long are globally respected leaders whose careers have been defined by visionary leadership, strategic insight, and strong track records of driving growth and operational excellence at consumer-focus...

BURLINGAME, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder with no approved therapies. The licensing of vantictumab represents a strategic expansion of āshibio’s p...

AMSTERDAM & HONG KONG & OAKLAND, Calif.--(BUSINESS WIRE)--Cascale's 2025 Annual Meeting flagship event promises impactful dialogue and collaboration to accelerate progress and catalyze impact at scale....

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 18, 2025 (the “Meeting”). There were 90 shareholders represented in person or by proxy at the...